Markus Meriläinen

914 total citations
16 papers, 685 citations indexed

About

Markus Meriläinen is a scholar working on Clinical Biochemistry, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Markus Meriläinen has authored 16 papers receiving a total of 685 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Clinical Biochemistry, 7 papers in Molecular Biology and 7 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Markus Meriläinen's work include Metabolism and Genetic Disorders (10 papers), Mitochondrial Function and Pathology (4 papers) and Diabetes Treatment and Management (4 papers). Markus Meriläinen is often cited by papers focused on Metabolism and Genetic Disorders (10 papers), Mitochondrial Function and Pathology (4 papers) and Diabetes Treatment and Management (4 papers). Markus Meriläinen collaborates with scholars based in United States, Germany and United Kingdom. Markus Meriläinen's co-authors include Lawrence Blonde, P. Raskin, Vatsala Karwe, Deborah A. Bilder, Christoph Koenen, Suyash Prasad, Haoling H. Weng, Cary O. Harding, Jerry Vockley and Joy Jiang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Pharmacokinetics and Diabetes Obesity and Metabolism.

In The Last Decade

Markus Meriläinen

16 papers receiving 651 citations

Peers

Markus Meriläinen

CB

EDM

MB

PHYSI

GENET

Mojca Žerjav Tanšek Slovenia

Norma Spécola Argentina

Anuja Agarwala India

Kikumaro Aoki Japan

Adelheid Wiemer‐Kruel Germany

Maria Elisa Paiva Pires Brazil

Petra Trimmel‐Schwahofer Austria

Judy Nation Australia

Tanya J. W. McDonald United States

Orkide Güzel Türkiye

Mojca Žerjav Tanšek Slovenia

Markus Meriläinen

216 ×0.6

CB

64 ×0.2

EDM

209 ×0.7

MB

177 ×0.8

PHYSI

101 ×0.9

GENET

Citations per year, relative to Markus Meriläinen Markus Meriläinen (= 1×) peers Mojca Žerjav Tanšek

Countries citing papers authored by Markus Meriläinen

Since Specialization

Citations

This map shows the geographic impact of Markus Meriläinen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Meriläinen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Meriläinen more than expected).

Fields of papers citing papers by Markus Meriläinen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Meriläinen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Meriläinen. The network helps show where Markus Meriläinen may publish in the future.

Co-authorship network of co-authors of Markus Meriläinen

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Meriläinen. A scholar is included among the top collaborators of Markus Meriläinen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Meriläinen. Markus Meriläinen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

1.

Bilder, Deborah A., Georgianne L. Arnold, David Dimmock, et al.. (2021). Improved attention linked to sustained phenylalanine reduction in adults with early‐treated phenylketonuria. American Journal of Medical Genetics Part A. 188(3). 768–778. 17 indexed citations

2.

Henshaw, Joshua, Soumi Gupta, Joy Olbertz, et al.. (2021). Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria. Clinical and Translational Science. 14(5). 1894–1905. 14 indexed citations

3.

Harding, Cary O., Roberto Amato, Nicola Longo, et al.. (2018). Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial. PMC. 1 indexed citations

4.

Thomas, Janet A., Harvey L. Levy, Stephen Amato, et al.. (2018). Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). Molecular Genetics and Metabolism. 124(1). 27–38. 134 indexed citations

5.

Harding, Cary O., Roberto Amato, Nicola Longo, et al.. (2018). Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial. Molecular Genetics and Metabolism. 124(1). 20–26. 60 indexed citations

6.

Bilder, Deborah A., et al.. (2016). Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults With Phenylketonuria. Developmental Neuropsychology. 41(4). 245–260. 99 indexed citations

7.

Wyrwich, Kathleen W., Katharine S. Gries, Elizabeth D. Bacci, et al.. (2016). Assessing the Content Validity of the Investigator-Rated ADHD Rating Scale Version IV Instrument Inattention Subscale for Use in Adults With Phenylketonuria. SHILAP Revista de lepidopterología. 4. 4078079097–4078079097. 1 indexed citations

8.

Bacci, Elizabeth D., Kathleen W. Wyrwich, Katharine S. Gries, et al.. (2016). An Adaptation of the Profile of Mood States for Use in Adults With Phenylketonuria. SHILAP Revista de lepidopterología. 4. 4078079097–4078079097. 5 indexed citations

9.

Wyrwich, Kathleen W., Priscilla Auguste, Ren Yu, et al.. (2015). Evaluation of Neuropsychiatric Function in Phenylketonuria: Psychometric Properties of the ADHD Rating Scale-IV and Adult ADHD Self-Report Scale Inattention Subscale in Phenylketonuria. Value in Health. 18(4). 404–412. 16 indexed citations

10.

Mould, Diane R., et al.. (2014). A Prospective Population Pharmacokinetic Analysis of Sapropterin Dihydrochloride in Infants and Young Children with Phenylketonuria. Clinical Pharmacokinetics. 54(2). 195–207. 8 indexed citations

11.

Auguste, Priscilla, et al.. (2014). Psychometric Properties Of The Adhd Rating Scale-Iv (Adhd Rs-Iv) And Adult Adhd Self-Report Scale (Asrs) In A Phase 3b Clinical Trial Of Patients With Phenylketonuria. Value in Health. 17(3). A231–A231. 2 indexed citations

12.

Burton, Barbara K., Mitzie Grant, Annette Feigenbaum, et al.. (2014). A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria. Molecular Genetics and Metabolism. 114(3). 415–424. 42 indexed citations

13.

Blonde, Lawrence, et al.. (2009). Patient‐directed titration for achieving glycaemic goals using a once‐daily basal insulin analogue: an assessment of two different fasting plasma glucose targets ‐ the TITRATE ^TM study. Diabetes Obesity and Metabolism. 11(6). 623–631. 137 indexed citations

14.

Dornhorst, Anne, et al.. (2007). Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal‐only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14‐week follow‐up data from PREDICTIVE™. Diabetes Obesity and Metabolism. 10(1). 75–81. 46 indexed citations

15.

Dornhorst, Anne, et al.. (2007). Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Current Medical Research and Opinion. 24(2). 369–376. 23 indexed citations

16.

Koenen, Christoph, et al.. (2006). Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study*. Diabetes Obesity and Metabolism. 9(3). 418–427. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact